Sign in
CompletedNo phase

A Prospective Multicenter Cohort Study on Surgical Treatment Strategies for Pediatric Mitral Regurgitation

Key facts

Who runs it
China National Center for Cardiovascular Diseases
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
427 people enrolled
Started
18 Mar 2020
Ended
20 Sept 2025
Type of study
Observational, 2 groups
Treatments tested
  • conventional mitral valve repair
  • standardized mitral valve repair
Record updated
16 December 2025

Who can take part

Age
Up to 14 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age < 14 years
  • No prior mitral valve surgery
  • Preoperative echocardiography demonstrating moderate or severe mitral regurgitation

Who cannot take part

  • Concomitant cardiac malformations unable to be corrected simultaneously
  • Connective tissue disorders(e.g., Barlow's disease, Marfan syndrome)
  • Moderate or severe mitral stenosis
  • Ischemic mitral regurgitation
  • Severe leaflet dysplasia precluding adequate coaptation
  • Any type of cardiomyopathy
  • Single ventricle physiology or common atrioventricular valve

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective, multicenter cohort study aims to evaluate the outcomes of surgical repair for pediatric mitral regurgitation (MR) in China. From March 2020 to December 2024, consecutive patients younger than 14 years who underwent mitral valve repair at eight representative congenital heart disease centers were enrolled. Eligible patients were those with at least moderate MR on preoperative echocardiography and no prior mitral valve surgery. Patients with uncorrectable concomitant cardiac anomalies, moderate or greater mitral stenosis, ischemic MR, severe leaflet dysplasia, connective tissue disorders (e.g., Barlow, Marfan), cardiomyopathies, or single-ventricle physiology were excluded.

Read full original descriptionShow less

The primary endpoint is a composite of all-cause mortality, reoperation for cardiovascular causes, or recurrence of moderate-or-severe MR during follow-up. Secondary endpoints include perioperative outcomes such as postoperative hospital stay, intensive care unit stay, mechanical ventilation time, and hospitalization cost.

This study is designed to provide high-quality prospective evidence on the safety, durability, and predictors of surgical repair for pediatric MR in a contemporary, real-world, multicenter setting. The findings may inform surgical decision-making and postoperative management strategies for this rare but challenging population.

The 2 groups in the trial

  • Conventional Group

    Those who have undergone conventional mitral valve repair

    Treatment: conventional mitral valve repair

  • Standardized Group

    Those who have undergone standardized mitral valve repair

    Treatment: standardized mitral valve repair

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 December 2025